Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 516 entries
Sorted by: Best Match Show Resources per page
Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria.

Iranian journal of pharmaceutical research : IJPR

Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M, Niknahad H.
PMID: 26330870
Iran J Pharm Res. 2015;14(3):825-32.

Pioglitazone (PG) is one of thiazolidinediones used for the treatment of type II diabetes mellitus. Some reports of its hepatotoxicity exist, but the mechanism of its hepatotoxicity is not well known. In the present study, the protective effect of...

Cite
Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M, et al. Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria. Iran J Pharm Res. 2015;14(3):825-32
Rezaiean Mehrabadi, A., Jamshidzadeh, A., Rashedinia, M., & Niknahad, H. (2015). Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria. Iranian journal of pharmaceutical research : IJPR, 14(3), 825-32.
Rezaiean Mehrabadi, Abbas, et al. "Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria." Iranian journal of pharmaceutical research : IJPR vol. 14,3 (2015): 825-32.
Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M, Niknahad H. Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria. Iran J Pharm Res. 2015;14(3):825-32. PMID: 26330870; PMCID: PMC4518110.
Copy Download .nbib Format: NLM
Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy.

Journal of drug assessment

McFarland MS, Huddleston L, Tammareddi K, McKenzie M, Bean J.
PMID: 27536426
J Drug Assess. 2012 Jun 29;1(1):34-9. doi: 10.3109/21556660.2012.707996. eCollection 2012.

OBJECTIVES: It has been proposed that the combination of thiazolidinedione (TZD) therapy to metformin and sulfonylurea is beneficial due to each medication having a unique mechanism of action. Within the Veterans Affairs Hospital, specific criteria of use define when...

Cite
McFarland MS, Huddleston L, Tammareddi K, et al. Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. J Drug Assess. 2012;1(1):34-9doi: 10.3109/21556660.2012.707996.
McFarland, M. S., Huddleston, L., Tammareddi, K., McKenzie, M., & Bean, J. (2012). Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. Journal of drug assessment, 1(1), 34-9. https://doi.org/10.3109/21556660.2012.707996
McFarland, M Shawn, et al. "Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy." Journal of drug assessment vol. 1,1 (2012): 34-9. doi: https://doi.org/10.3109/21556660.2012.707996
McFarland MS, Huddleston L, Tammareddi K, McKenzie M, Bean J. Comparison of hemoglobin A1c goal achievement with the addition of pioglitazone to maximal/highest tolerated doses of sulfonylurea and metformin combination therapy. J Drug Assess. 2012 Jun 29;1(1):34-9. doi: 10.3109/21556660.2012.707996. eCollection 2012. PMID: 27536426; PMCID: PMC4980726.
Copy Download .nbib Format: NLM
Effect of resveratrol on cancer progression through the REG Ⅲ expression pathway in head and neck cancer cells.

International journal of oncology

Mikami S, Ota I, Masui T, Itaya-Hironaka A, Shobatake R, Okamoto H, Takasawa S, Kitahara T.
PMID: 27633858
Int J Oncol. 2016 Oct;49(4):1553-1560. doi: 10.3892/ijo.2016.3664. Epub 2016 Aug 19.

Identification of reliable markers of chemo- and radiosensitivity and the key molecules that enhance the susceptibility of head and neck squamous cell carcinoma (HNSCC) to anticancer treatments is highly desirable. Previously, we have reported that regenerating gene (REG) Ⅲ...

Cite
Mikami S, Ota I, Masui T, et al. Effect of resveratrol on cancer progression through the REG Ⅲ expression pathway in head and neck cancer cells. Int J Oncol. 2016;49(4):1553-1560doi: 10.3892/ijo.2016.3664.
Mikami, S., Ota, I., Masui, T., Itaya-Hironaka, A., Shobatake, R., Okamoto, H., Takasawa, S., & Kitahara, T. (2016). Effect of resveratrol on cancer progression through the REG Ⅲ expression pathway in head and neck cancer cells. International journal of oncology, 49(4), 1553-1560. https://doi.org/10.3892/ijo.2016.3664
Mikami, Shinji, et al. "Effect of resveratrol on cancer progression through the REG Ⅲ expression pathway in head and neck cancer cells." International journal of oncology vol. 49,4 (2016): 1553-1560. doi: https://doi.org/10.3892/ijo.2016.3664
Mikami S, Ota I, Masui T, Itaya-Hironaka A, Shobatake R, Okamoto H, Takasawa S, Kitahara T. Effect of resveratrol on cancer progression through the REG Ⅲ expression pathway in head and neck cancer cells. Int J Oncol. 2016 Oct;49(4):1553-1560. doi: 10.3892/ijo.2016.3664. Epub 2016 Aug 19. PMID: 27633858.
Copy Download .nbib Format: NLM
Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR.

PPAR research

Pan DS, Wang W, Liu NS, Yang QJ, Zhang K, Zhu JZ, Shan S, Li ZB, Ning ZQ, Huang L, Lu XP.
PMID: 29056962
PPAR Res. 2017;2017:4313561. doi: 10.1155/2017/4313561. Epub 2017 Sep 19.

Type 2 diabetes mellitus is often treated with insulin-sensitizing drugs called thiazolidinediones (TZD), which improve insulin resistance and glycemic control. Despite their effectiveness in treating diabetes, these drugs provide little protection from eminent cardiovascular disease associated with diabetes. Here...

Cite
Pan DS, Wang W, Liu NS, et al. Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR. PPAR Res. 2017;2017:4313561doi: 10.1155/2017/4313561.
Pan, D. S., Wang, W., Liu, N. S., Yang, Q. J., Zhang, K., Zhu, J. Z., Shan, S., Li, Z. B., Ning, Z. Q., Huang, L., & Lu, X. P. (2017). Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR. PPAR research, 20174313561. https://doi.org/10.1155/2017/4313561
Pan, De-Si, et al. "Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR." PPAR research vol. 2017 (2017): 4313561. doi: https://doi.org/10.1155/2017/4313561
Pan DS, Wang W, Liu NS, Yang QJ, Zhang K, Zhu JZ, Shan S, Li ZB, Ning ZQ, Huang L, Lu XP. Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR. PPAR Res. 2017;2017:4313561. doi: 10.1155/2017/4313561. Epub 2017 Sep 19. PMID: 29056962; PMCID: PMC5625810.
Copy Download .nbib Format: NLM
Thiazolidinediones and bone fractures.

Journal of diabetes investigation

Kaku K, Hashiramoto M.
PMID: 24843512
J Diabetes Investig. 2011 Oct 07;2(5):354-5. doi: 10.1111/j.2040-1124.2011.00142.x.

No abstract available.

Cite
Kaku K, Hashiramoto M. Thiazolidinediones and bone fractures. J Diabetes Investig. 2011;2(5):354-5doi: 10.1111/j.2040-1124.2011.00142.x.
Kaku, K., & Hashiramoto, M. (2011). Thiazolidinediones and bone fractures. Journal of diabetes investigation, 2(5), 354-5. https://doi.org/10.1111/j.2040-1124.2011.00142.x
Kaku, Kohei, and Hashiramoto, Mitsuru. "Thiazolidinediones and bone fractures." Journal of diabetes investigation vol. 2,5 (2011): 354-5. doi: https://doi.org/10.1111/j.2040-1124.2011.00142.x
Kaku K, Hashiramoto M. Thiazolidinediones and bone fractures. J Diabetes Investig. 2011 Oct 07;2(5):354-5. doi: 10.1111/j.2040-1124.2011.00142.x. PMID: 24843512; PMCID: PMC4019301.
Copy Download .nbib Format: NLM
Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet.

Current therapeutic research, clinical and experimental

Akbay E, Ulusu NN, Töröner F, Ayvaz G, Taneri F, Aktürk M, Arslan M, Karasu C.
PMID: 24936106
Curr Ther Res Clin Exp. 2004 Jan;65(1):79-89. doi: 10.1016/S0011-393X(04)90007-0.

BACKGROUND: Animals fed high-fat diets have been shown to develop hyperglycemia, insulin resistance, hyperlipidemia, and moderate obesity, which resemble the human metabolic syndrome. Obesity, the metabolic syndrome, and some thiazolidinediones, which act as insulin sensitizers, may increase oxidative stress,...

Cite
Akbay E, Ulusu NN, Töröner F, et al. Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet. Curr Ther Res Clin Exp. 2004;65(1):79-89doi: 10.1016/S0011-393X(04)90007-0.
Akbay, E., Ulusu, N. N., Töröner, F., Ayvaz, G., Taneri, F., Aktürk, M., Arslan, M., & Karasu, C. (2004). Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet. Current therapeutic research, clinical and experimental, 65(1), 79-89. https://doi.org/10.1016/S0011-393X(04)90007-0
Akbay, Esen, et al. "Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet." Current therapeutic research, clinical and experimental vol. 65,1 (2004): 79-89. doi: https://doi.org/10.1016/S0011-393X(04)90007-0
Akbay E, Ulusu NN, Töröner F, Ayvaz G, Taneri F, Aktürk M, Arslan M, Karasu C. Effects of rosiglitazone treatment on the pentose phosphate pathway and glutathione-dependent enzymes in liver and kidney of rats fed a high-fat diet. Curr Ther Res Clin Exp. 2004 Jan;65(1):79-89. doi: 10.1016/S0011-393X(04)90007-0. PMID: 24936106; PMCID: PMC4052959.
Copy Download .nbib Format: NLM
Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.

Journal of diabetes investigation

Nauck MA, Vardarli I.
PMID: 24843405
J Diabetes Investig. 2010 Apr 22;1(1):24-36. doi: 10.1111/j.2040-1124.2010.00004.x.

UNLABELLED: Aims/Introduction:  To compare clinical consequences of using inretin-based medications versus conventional antidiabetic agents as add-on to metformin in case of monotherapy failure in patients with type 2 diabetes.MATERIALS AND METHODS:   The medical literature including recent abstracts from international...

Cite
Nauck MA, Vardarli I. Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig. 2010;1(1):24-36doi: 10.1111/j.2040-1124.2010.00004.x.
Nauck, M. A., & Vardarli, I. (2010). Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. Journal of diabetes investigation, 1(1), 24-36. https://doi.org/10.1111/j.2040-1124.2010.00004.x
Nauck, Michael A, and Vardarli, Irfan. "Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure." Journal of diabetes investigation vol. 1,1 (2010): 24-36. doi: https://doi.org/10.1111/j.2040-1124.2010.00004.x
Nauck MA, Vardarli I. Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig. 2010 Apr 22;1(1):24-36. doi: 10.1111/j.2040-1124.2010.00004.x. PMID: 24843405; PMCID: PMC4020674.
Copy Download .nbib Format: NLM
Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity.

Diabetes & metabolism journal

Corzo C, Griffin PR.
PMID: 24404510
Diabetes Metab J. 2013 Dec;37(6):395-403. doi: 10.4093/dmj.2013.37.6.395.

Adipose tissue, which was once viewed as a simple organ for storage of triglycerides, is now considered an important endocrine organ. Abnormal adipose tissue mass is associated with defects in endocrine and metabolic functions which are the underlying causes...

Cite
Corzo C, Griffin PR. Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes Metab J. 2013;37(6):395-403doi: 10.4093/dmj.2013.37.6.395.
Corzo, C., & Griffin, P. R. (2013). Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes & metabolism journal, 37(6), 395-403. https://doi.org/10.4093/dmj.2013.37.6.395
Corzo, Cesar, and Griffin, Patrick R. "Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity." Diabetes & metabolism journal vol. 37,6 (2013): 395-403. doi: https://doi.org/10.4093/dmj.2013.37.6.395
Corzo C, Griffin PR. Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes Metab J. 2013 Dec;37(6):395-403. doi: 10.4093/dmj.2013.37.6.395. PMID: 24404510; PMCID: PMC3881323.
Copy Download .nbib Format: NLM
Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice.

Endocrinology and metabolism (Seoul, Korea)

Kim KM, Jin HJ, Lee SY, Maeng HJ, Lee GY, Oh TJ, Choi SH, Jang HC, Lim S.
PMID: 28956370
Endocrinol Metab (Seoul). 2017 Sep;32(3):389-395. doi: 10.3803/EnM.2017.32.3.389.

BACKGROUND: Bone strength is impaired in patients with type 2 diabetes mellitus despite an increase in bone mineral density (BMD). Thiazolidinedione (TZD), a peroxisome proliferator activated receptor γ agonist, promotes adipogenesis, and suppresses osteoblastogenesis. Therefore, its use is associated...

Cite
Kim KM, Jin HJ, Lee SY, et al. Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice. Endocrinol Metab (Seoul). 2017;32(3):389-395doi: 10.3803/EnM.2017.32.3.389.
Kim, K. M., Jin, H. J., Lee, S. Y., Maeng, H. J., Lee, G. Y., Oh, T. J., Choi, S. H., Jang, H. C., & Lim, S. (2017). Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice. Endocrinology and metabolism (Seoul, Korea), 32(3), 389-395. https://doi.org/10.3803/EnM.2017.32.3.389
Kim, Kyoung Min, et al. "Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice." Endocrinology and metabolism (Seoul, Korea) vol. 32,3 (2017): 389-395. doi: https://doi.org/10.3803/EnM.2017.32.3.389
Kim KM, Jin HJ, Lee SY, Maeng HJ, Lee GY, Oh TJ, Choi SH, Jang HC, Lim S. Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice. Endocrinol Metab (Seoul). 2017 Sep;32(3):389-395. doi: 10.3803/EnM.2017.32.3.389. PMID: 28956370; PMCID: PMC5620037.
Copy Download .nbib Format: NLM
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.

Diabetes, metabolic syndrome and obesity : targets and therapy

Levin PA, Nguyen H, Wittbrodt ET, Kim SC.
PMID: 28435305
Diabetes Metab Syndr Obes. 2017 Apr 04;10:123-139. doi: 10.2147/DMSO.S130834. eCollection 2017.

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety.OBJECTIVE: Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) was systematically reviewed.METHODS: A literature...

Cite
Levin PA, Nguyen H, Wittbrodt ET, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123-139doi: 10.2147/DMSO.S130834.
Levin, P. A., Nguyen, H., Wittbrodt, E. T., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, metabolic syndrome and obesity : targets and therapy, 10123-139. https://doi.org/10.2147/DMSO.S130834
Levin, Philip A, et al. "Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 123-139. doi: https://doi.org/10.2147/DMSO.S130834
Levin PA, Nguyen H, Wittbrodt ET, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017 Apr 04;10:123-139. doi: 10.2147/DMSO.S130834. eCollection 2017. PMID: 28435305; PMCID: PMC5389657.
Copy Download .nbib Format: NLM
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.

Therapeutic advances in endocrinology and metabolism

Harris KB, McCarty DJ.
PMID: 25678952
Ther Adv Endocrinol Metab. 2015 Feb;6(1):3-18. doi: 10.1177/2042018814558242.

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and...

Cite
Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6(1):3-18doi: 10.1177/2042018814558242.
Harris, K. B., & McCarty, D. J. (2015). Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism, 6(1), 3-18. https://doi.org/10.1177/2042018814558242
Harris, Kira B, and McCarty, Delilah J. "Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus." Therapeutic advances in endocrinology and metabolism vol. 6,1 (2015): 3-18. doi: https://doi.org/10.1177/2042018814558242
Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015 Feb;6(1):3-18. doi: 10.1177/2042018814558242. PMID: 25678952; PMCID: PMC4321868.
Copy Download .nbib Format: NLM
Deciphering the Roles of Thiazolidinediones and PPAR.

PPAR research

Chiu M, McBeth L, Sindhwani P, Hinds TD.
PMID: 28348577
PPAR Res. 2017;2017:4810672. doi: 10.1155/2017/4810672. Epub 2017 Feb 28.

The use of thiazolidinedione (TZD) therapy in type II diabetic patients has proven useful in the lowering of blood glucose levels. However, recent investigations have shown that there may be potential health concerns associated, including the risk of developing...

Cite
Chiu M, McBeth L, Sindhwani P, et al. Deciphering the Roles of Thiazolidinediones and PPAR. PPAR Res. 2017;2017:4810672doi: 10.1155/2017/4810672.
Chiu, M., McBeth, L., Sindhwani, P., & Hinds, T. D. (2017). Deciphering the Roles of Thiazolidinediones and PPAR. PPAR research, 20174810672. https://doi.org/10.1155/2017/4810672
Chiu, Melody, et al. "Deciphering the Roles of Thiazolidinediones and PPAR." PPAR research vol. 2017 (2017): 4810672. doi: https://doi.org/10.1155/2017/4810672
Chiu M, McBeth L, Sindhwani P, Hinds TD. Deciphering the Roles of Thiazolidinediones and PPAR. PPAR Res. 2017;2017:4810672. doi: 10.1155/2017/4810672. Epub 2017 Feb 28. PMID: 28348577; PMCID: PMC5350343.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 516 entries